- Trial phase
- Preclinical
- Time to market
- Unknown; MAR003 is preclinical and no clinical trial enrollment has been publicly identified. If it follows the siRNA development path, it would likely be several years from potential commercialization.
- Why 2/10
- No hard dated catalyst is scheduled for MAR003 in the next ~12 months; it is a preclinical IPR&D asset with no publicly identified clinical trial enrollment, PDUFA date, or regulatory milestone. The score is limited to 2 because the drug is preclinical with no upcoming binary event, even though it is part of the company's pipeline narrative.
MAR003 is too early-stage (preclinical) to drive LSTA's near-term share price. Investors should instead focus on the November 30, 2026 annual meeting vote for Series C conversion (which unlocks the ~350M share resale registration overhang) and on upcoming clinical catalysts for MAR001 (Phase 2b hypertriglyceridemia data presented at AHA Nov 6-9, 2026) and MAR002 (Phase 2 acromegaly trial enrollment).
Price Chart
Executive Summary
MAR003 is a preclinical-stage cardioendocrine drug candidate from Marea Therapeutics, which was acquired by Lisata Therapeutics (LSTA) in a September 2026 reverse merger backed by a $225 million private placement. Very little public information exists about MAR003's specific mechanism or target, though it is believed to be part of Marea's siRNA platform. It was valued as an in-process research and development (IPR&D) asset in the acquisition's purchase price allocation, sharing a $292.9M allocation with the more advanced MAR001/005 and MAR002 programs. MAR003 has no clinical trials registered, no disclosed development timeline, and no imminent catalysts. For LSTA investors, MAR003 is a distant future story; the company's near-term value drivers are the MAR001 Phase 2b data (recently reported positive at AHA 2026), the MAR002 Phase 2 acromegaly trial, and the high-stakes November 30 shareholder vote on Series C preferred stock conversion.
How It Works
MAR003 is a preclinical cardioendocrine drug candidate within Marea Therapeutics' (now a Lisata subsidiary) pipeline. Based on context from company statements about an 'siRNA platform expanding,' it is likely an siRNA-based (gene-silencing) therapy targeting an undisclosed cardiometabolic disease pathway. No specific mechanism has been publicly disclosed as of November 2026.
Trial Status
MAR003 is a preclinical-stage candidate. No clinical trials have been registered on ClinicalTrials.gov and no specific mechanism or target has been publicly disclosed as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- November 30, 2026: Lisata annual meeting adjourned for shareholder vote on Series C preferred stock conversion (critical to unlocking the Marea/PIPE financing structure).
- Late 2026/Early 2027: Potential next steps for MAR002 Phase 2 acromegaly trial enrollment updates.
- No near-term catalysts identified for MAR003 specifically.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LISATA THERAPEUTICS, INC. 8-K/A LSTA ·Originating report